Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival

Am J Hematol. 2015 Sep;90(9):E197-9. doi: 10.1002/ajh.24100. Epub 2015 Aug 14.

Authors

Aurélie Jaspers¹, Frédéric Baron¹, Sophie Servais¹, Marie Lejeune¹, Évelyne Willems¹, Laurence Seidel², Kaoutar Hafraoui¹, Christophe Bonnet¹, Yves Beguin¹

Affiliations

¹ Division of Hematology, Department of Medicine, CHU of Liège and University of Liège, Liège, Belgium.
² Department of Statistics, SIME, CHU of Liège, Liège, Belgium.

PMID: 26113363
DOI: 10.1002/ajh.24100

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use*
Erythropoietin / therapeutic use*
Hematologic Neoplasms / complications
Hematologic Neoplasms / mortality
Hematologic Neoplasms / pathology
Hematologic Neoplasms / therapy*
Hematopoietic Stem Cell Transplantation*
Humans
Opportunistic Infections / complications
Opportunistic Infections / mortality
Opportunistic Infections / pathology
Opportunistic Infections / therapy*
Survival Analysis
Transplantation Conditioning*
Transplantation, Homologous
Treatment Outcome

Substances

Antineoplastic Agents
Erythropoietin